Novel recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Patent Application 20070122999

Modified recombinant DAOs with reduced GAG binding affinity address the limitations of current antihistamines by extending plasma half-life and enhancing histamine breakdown, offering effective treatment for severe histamine-related conditions.

JP7792252B2Active Publication Date: 2025-12-25MEDICINISCHE UNIBERGITATE VIENNA +1
5 Cites 0 Cited by

Patent Information

Application Number
JP2021548232
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-19
Filing Date
2020-02-18
Publication Date
2025-12-25
Estimated Expiration
2040-02-18

AI Technical Summary

Technical Problem

Current antihistamines are ineffective in managing high histamine levels, particularly during anaphylactic reactions and conditions associated with mastocytosis, leading to severe and life-threatening symptoms, and existing recombinant diamine oxidases (DAOs) have poor pharmacokinetic profiles, limiting their therapeutic potential.

Method used

Development of recombinant human DAOs with reduced glycosaminoglycan binding affinity through amino acid modifications, specifically in the GAG binding domain, to enhance plasma half-life and enzymatic activity, thereby effectively breaking down excess histamine.

Benefits of technology

The modified DAOs exhibit significantly extended plasma half-life and reduced clearance, effectively decomposing excess histamine, providing a new treatment option for conditions like anaphylaxis, chronic urticaria, and other histamine-induced diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a recombinant human diamine oxidase (DAO) with reduced glycosaminoglycan binding affinity, said DAO comprising at least one amino acid modification in the glycosaminoglycan (GAG)-binding domain. The present invention further relates to the use of DAO in the treatment of conditions associated with excess histamine, particularly in the treatment of chronic allergic diseases, more particularly in the treatment of anaphylaxis, anaphylactic shock, chronic urticaria, acute urticaria, asthma, hay fever, allergic rhinitis, allergic conjunctivitis, histamine poisoning, headache, atopic dermatitis, inflammatory diseases, mastocytosis, mast cell activation syndrome (MCAS), pre-eclampsia, hyperemesis gravidarum, preterm labor, peptic ulcer, acid reflux, pruritus, and sepsis.
Need to check novelty before this filing date? Find Prior Art